scholarly journals Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection

2017 ◽  
Vol 66 (37) ◽  
pp. 990-994 ◽  
Author(s):  
Naomi K. Tepper ◽  
Jamie W. Krashin ◽  
Kathryn M. Curtis ◽  
Shanna Cox ◽  
Maura K. Whiteman
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Contraceptive Use ◽  
Hormonal Contraception ◽  
Eligibility Criteria

Validation of measures of condom and other contraceptive use among women at high risk for HIV infection and unitended pregnancy.

1995 ◽  
Vol 14 (6) ◽  
pp. 570-578 ◽  
Author(s):  
Christine Galavotti ◽  
Rebecca J. Cabral ◽  
Amy Lansky ◽  
Diane M. Grimley ◽  
Gabrielle E. Riley ◽  
...  
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Contraceptive Use

Contraception Options in Neurologic Disease

2018 ◽  
Author(s):  
Tessa L. Reisinger ◽  
Amy Robinson Harrington
Keyword(s):  
Chronic Disease ◽  
Contraceptive Use ◽  
Unplanned Pregnancy ◽  
Treatment Options ◽  
Hormonal Contraception ◽  
Neurologic Disease ◽  
Eligibility Criteria ◽  
Increased Risk ◽  
Wide Range ◽  
The Impact

Unplanned pregnancy has particular implications for women with chronic disease, including increased risk of adverse health events during pregnancy and potential impact on disease course or treatment options. While preventing unplanned pregnancy is especially important in this population, both medications and sequelae of chronic disease must be considered in choosing safe and effective contraceptive options. The US Medical Eligibility Criteria for Contraceptive Use were established to provide guidance on contraceptive use for women with various disease conditions; however, specific guidelines for many neurologic conditions are limited. This chapter reviews evidence and recommendations for contraception options in women with a wide range of neurologic conditions. Considerations include interactions with medications, the risk of venous thromboembolism in the setting of reduced mobility, and the impact of hormonal contraception on symptom frequency and disease progression. In many cases, long-acting reversible contraception (LARC) methods offer highly effective, well-tolerated contraception for women with neurologic disease.

Breaking down barriers to birth control access: An assessment of online platforms prescribing birth control in the USA

2019 ◽  
Vol 26 (6) ◽  
pp. 322-331 ◽  
Author(s):  
Carmela Zuniga ◽  
Daniel Grossman ◽  
Sara Harrell ◽  
Kelly Blanchard ◽  
Kate Grindlay
Keyword(s):  
Birth Control ◽  
Contraceptive Use ◽  
Insurance Coverage ◽  
Hormonal Contraception ◽  
Hormonal Contraceptives ◽  
Eligibility Criteria ◽  
Online Platforms ◽  
Significant Barrier ◽  
The Usa ◽  
Evidence Based Care

Introduction In the USA, the requirement that individuals obtain a prescription for hormonal contraception is a significant barrier for women who lack the time, finances, insurance coverage or means of transportation to visit a provider. The emergence of telemedicine services has removed some of these barriers by providing women with the opportunity to conveniently obtain birth control prescriptions through their computer or smartphone. Methods In this article, we compare the prescribing processes and policies of online platforms that prescribe hormonal contraceptives to women in the USA, and use the recommendations of the 2016 US medical eligibility criteria for contraceptive use to evaluate whether online prescribers are providing evidence-based care. Results As of February 2018, nine online platforms prescribed hormonal birth control to women across various states in the USA. These platforms varied in regard to their prescribing processes, range of methods offered, locations of operation, fees for services, and policies regarding age restrictions. Discussion An assessment of each platform’s online health questionnaire reveals that these telemedicine services are adequately screening for contraindications and safely providing birth control methods to patients, although efforts could be made to strengthen the rigour of online health questionnaires to ensure they adequately screen for all contraindications.

scholarly journals Trichomonas vaginalis Incidence Associated with Hormonal Contraceptive Use and HIV Infection among Women in Rakai, Uganda

2014 ◽  
Vol 2014 ◽  
pp. 1-10
Author(s):  
Heena Brahmbhatt ◽  
Richard Musoke ◽  
Frederick Makumbi ◽  
Godfrey Kigozi ◽  
David Serwadda ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Poisson Regression ◽  
Regression Models ◽  
Trichomonas Vaginalis ◽  
Contraceptive Use ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Sexually Active ◽  
Rate Ratios

Background. Data on the incidence of Trichomonas vaginalis and use of hormonal contraception (HC) are limited. Methods. 2,374 sexually active women aged 15–49 years from cohort surveys in Rakai, Uganda, were included. Incidence of T. vaginalis was estimated per 100 person years (py) and association between HC (DMPA, Norplant, and oral contraceptives) and T. vaginalis infection was assessed by incidence rate ratios (IRR), using Poisson regression models. Results. At baseline, 34.9% had used HC in the last 12 months, 12.8% HIV+, 39.7% with high BV-scores (7–10), and 3.1% syphilis positive. The 12-month incidence of T. vaginalis was 2.4/100 py; CI (1.90, 3.25). When stratified by type of HC used, compared to women who did not use HC or condoms, incidence of T. vaginalis was significantly higher among users of Norplant (adj.IRR = 3.01, CI: 1.07–8.49) and significantly lower among DMPA users (adj.IRR = 0.55, CI: 0.30, 0.98) and women who discontinued HC use at follow-up (adj.IRR = 0.30, CI: 0.09, 0.99). HIV infection was associated with an increase in incidence of T. vaginalis (adj.IRR = 2.34, CI: 1.44, 3.78). Conclusions. Use of Norplant and being HIV+ significantly increased the risk of T. vaginalis, while use of DMPA and discontinuation of overall HC use were associated with a decreased incidence of T. vaginalis.

Barrier contraceptive use and HIV infection among high-risk women in Cameroon

AIDS ◽  
1993 ◽  
Vol 7 (5) ◽  
pp. 725-732 ◽  
Author(s):  
Leopold Zekeng ◽  
Paul J. Feldblum ◽  
Regina M. Oliver ◽  
Lazare Kaptue
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Contraceptive Use ◽  
High Risk Women

Runaway Teens at High Risk of HIV Infection

1998 ◽  
Author(s):  
R. E. Booth ◽  
◽  
Y. Zhang
Keyword(s):  
High Risk ◽  
Hiv Infection

Contraception and thrombophilia

2009 ◽  
Vol 29 (02) ◽  
pp. 193-196 ◽  
Author(s):  
H. Rott ◽  
A. Kruempel ◽  
G. Kappert ◽  
U. Nowak-Göttl ◽  
S. Halimeh
Keyword(s):  
Chronic Illness ◽  
High Risk ◽  
Children And Adolescents ◽  
Hormonal Contraception ◽  
Hormonal Contraceptives ◽  
Thromboembolic Events ◽  
Contraceptive Methods ◽  
Secondary Complications ◽  
Increased Risk ◽  
Coagulation Proteins

SummaryThe risk of thromboembolic events (TE) is increased by acquired or inherited thrombo -philias (IT). We know that some hormonal contraceptives also increase the risk of thrombosis, thus, the use of such contraceptives are discussed as contraindications in women with IT. TEs are infrequent events in children and adolescents and in the majority of cases are associated with secondary complications from underlying chronic illness. Although adolescents are not typically considered to be at high-risk for TE, this cohort is frequently using hormonal contraception, leading to an increased risk in cases with unknown IT. The risk of TE with pregnancy alone is higher than associated with combined hormonal contra -ception. Progestin-only methods have not been found to increase the risk of TE with only moderate changes of coagulation proteins compared to normal reference values. Conclusion: Thrombophilic women are good candidates for progestin-only contraceptive methods.

Sign in / Sign up

Export Citation Format

Share Document